Veracyte: How To Build A Molecular Cytology Company

Veracyte has launched a complex molecular diagnostic test in thyroid in record time and with impressive capital efficiency. It could be a model for high-value diagnostics, especially if the company can successfully adopt its approach in a broader market.

The molecular cytology firm Veracyte Inc. arose in 2008 out of Calderome, an incubator formed by West Coast venture capital firms Kleiner Perkins Caufield & Byers (KPCB), TPG, and Versant Ventures. As they did with their other endeavors in molecular diagnostics in the 2000s, the VCs emphasized the need to understand the pharmacoeconomics of a potential new diagnostic test early on and to have a clear vision of how the test could influence clinical decision making.

Veracyte held to these founding precepts in deciding on its first clinical program, the development of a complex gene expression...

More from Archive

More from In Vivo

AI In The Loop: How Astellas Is Accelerating Oncology Drug Discovery

 
• By 

Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.

BioBytes: Israeli-US Startup Introduces Platform For Accelerated Clinical Data Analysis

 
• By 

A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.

The Dementia Disparity: Rethinking Alzheimer’s Through The Female Lens

 
• By 

Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.